GlobeNewswire
- FDA accepts supplemental Biologics License Application for Roche’s Lunsumio and Polivy combination for people with relapsed or refractory large B-cell lymphomaBasel, June 18, 2026 – Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that the US Food and Drug Administration… Read more »
- F2G and Shionogi Announce Positive Topline Results From Global Phase 3 OASIS Study Evaluating Oral Olorofim Versus AmBisome® Followed by Standard of Care in Patients With Invasive AspergillosisMANCHESTER, United Kingdom and OSAKA, Japan, June 18, 2026 (GLOBE NEWSWIRE) — F2G Ltd and Shionogi & Co., Ltd (Head… Read more »
- Legend Biotech Corporation Announces Pricing of Public OfferingBRIDGEWATER, N.J., June 17, 2026 (GLOBE NEWSWIRE) — Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech” or the “Company”), a global… Read more »
- MediPharm Labs Announces Voting Results from the 2026 Annual and Special Meeting of ShareholdersMediPharm Labs announces the results of matters voted on at its annual and special meeting of shareholders held today. Read more »
- Biogen Expands Immunology Pipeline with Agreement to Acquire RayThera Inc.Acquisition adds multiple immunology assets to Biogen’s portfolio, including a lead asset poised to enter Phase 1 development Acquisition adds… Read more »
- Zelluna ASA – Mandatory notification of trade – Subscription and share lending in Private PlacementOslo, 18 June 2027: Reference is made to the stock exchange announcement published by Zelluna ASA (the “Company”) on 17… Read more »
- Zelluna ASA: Private Placement and Retail Offering successfully placedNOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, HONG… Read more »
- Satellos Bioscience Announces Results of Annual Meeting of ShareholdersTORONTO, June 17, 2026 (GLOBE NEWSWIRE) — Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL) (“Satellos” or the “Company”), a clinical-stage biotechnology… Read more »
- Certara Announces CFO TransitionReaffirms 2026 Guidance Reaffirms 2026 Guidance Read more »
- Legend Biotech Corporation Announces Proposed Public OfferingBRIDGEWATER, N.J., June 17, 2026 (GLOBE NEWSWIRE) — Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech” or the “Company”), a global… Read more »
- Odyssey Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate UpdateReported positive clinical proof-of-concept data for OD-001 in a Phase 2a monotherapy trial for moderate to severe ulcerative colitis. Read more »
- Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)WALTHAM, Mass., June 17, 2026 (GLOBE NEWSWIRE) — Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global… Read more »
- Lexeo Therapeutics Announces Publication in JAMA Cardiology of Phase I/II Data for LX2006 in Friedreich AtaxiaPublished findings in JAMA Cardiology demonstrate LX2006 generally well tolerated, with early signs of efficacy in Phase I/II studies Read more »
- Cosmos Health Enters the $163 Billion Global Skincare Market; Sales Already Underway in the United StatesCosmos Health enters the global skincare market. Sales already underway in the United States. Read more »
- Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)CAMBRIDGE, Mass., June 17, 2026 (GLOBE NEWSWIRE) — Spero Therapeutics, Inc. (Nasdaq: SPRO) and GSK plc (LSE/NYSE: GSK) today announced… Read more »
- Minutes of the TME Pharma Annual General MeetingMinutes of the TME Pharma Annual General Meeting Read more »
- RESTEM to Present at BIO International ConventionMIAMI, June 17, 2026 (GLOBE NEWSWIRE) — RESTEM – a clinical-stage biotechnology company that develops off-the-shelf, next-generation cell therapies designed… Read more »
- Applied Biologics Announces Completion of Planned Enrollment Activities in the CAMPX Randomized Controlled Trial Evaluating XWRAP®Applied Biologics completes enrollment in the CAMPX RCT evaluating XWRAP® for chronic diabetic foot ulcers across 23 SerenaGroup sites. Read more »
- Zelluna ASA: Contemplated Private Placement and Retail Offering to Strengthen its Position Ahead of Initial Clinical DataNOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, HONG… Read more »
- Cosmos Health Signs 2.86 Million-Unit Contract Manufacturing Agreement With Pharmex S.A. Across Three Dermatological ProductsCosmos Health signs 1.72 million-unit contract manufacturing agreement With Pharmex S.A. across three dermatological products. Read more »
- NeOnc's Global Expansion Accelerates After Abu Dhabi IND Approval for NEO212NeOnc(NASDAQ: NTHI) is rapidly emerging as a development-stage neuro-oncology innovator Read more »
- Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)ORION CORPORATION STOCK EXCHANGE RELEASE / MAJOR SHAREHOLDER ANNOUNCEMENTS17 June 2026 at 16.00 EEST Read more »
BPGbio Presents Latest Clinical and Translational Findings Supporting BPM31510 in Primary CoQ10 Deficiency at Mito Med 2026
BOSTON, June 17, 2026 (GLOBE NEWSWIRE) — BPGbio, a clinical-stage biopharmaceutical company advancing mitochondrial-targeted therapeutics for patients, today presents new… Read more »- Connect Biopharma Announces Completion of Enrollment of Phase 2 Seabreeze STAT Asthma Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in Asthma– On track to also complete enrollment in the Seabreeze STAT COPD study this month – Read more »
- Precision Neuroscience™ Wins 2026 Webby Award; Earns Back-to-Back Fast Company World Changing Ideas HonorBoth recognitions cite the Layer 7 cortical interface and its potential to restore independence for people living with paralysis Both… Read more »
- Ocular Therapeutix™ Investor Day to Highlight U.S. FDA Alignment on AXPAXLI™ NDA with Submission Planned for Fourth Quarter 2026Per May 2026 Type C meeting, AXPAXLI NDA for wet AMD to be based on SOL-1 Week 52 efficacy and… Read more »
- Gelteq Provides Corporate Update: Launching Veterinary and Human Clinical Trials, Pharmaceutical Pipeline Expanding Across Multiple ProgramsCompany to present at Planet Microcap Conference in Las Vegas between June 16-18 Company to present at Planet Microcap Conference… Read more »
- Polyrizon Receives Notice of U.S. Patent Publication for Mucoadhesive Drug Delivery PlatformRaanana, Israel, June 17, 2026 (GLOBE NEWSWIRE) — Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development-stage biotech company… Read more »
- Avalyn Completes Target Enrollment in Phase 2b MIST Trial of AP01 (Inhaled Pirfenidone) for Patients with Progressive Pulmonary FibrosisCompany expects to report topline 12-month clinical results in the second half of 2027 Company expects to report topline 12-month… Read more »
- Oncotelic Advances AI-Powered GMP Manufacturing Services Platform for Revenue-Generating AI and Robotics Manufacturing ServicesSAN DIEGO, June 17, 2026 (GLOBE NEWSWIRE) — Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) (OTCQB: OTLC) today announced the… Read more »
- Merakris Therapeutics Awarded U.S. Department of Veterans Affairs Federal Supply Schedule Contract, Expanding Federal Market Access for Dermacyte® AC Matrix Amniotic Membrane AllograftMerakris Therapeutics Awarded U.S. Department of Veterans Affairs Federal Supply Schedule Contract Read more »
- Elicio Therapeutics Reports Multiple Complete Responses After ELI-002 7P Treatment and Subsequent Therapy with Checkpoint Inhibition in Metastatic mKRAS Pancreatic CancerBOSTON, Mass., June 17, 2026 (GLOBE NEWSWIRE) — Elicio Therapeutics, Inc. (Nasdaq: ELTX) (“Elicio” or the “Company”), a clinical-stage biotechnology… Read more »
- electroCore to Participate in iAccess Alpha Virtual Best Ideas Summer Investment ConferenceROCKAWAY, N.J., June 17, 2026 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today… Read more »
- Trevi Therapeutics Announces Upcoming June and July Event ScheduleNEW HAVEN, Conn., June 17, 2026 (GLOBE NEWSWIRE) — Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine… Read more »
- Dyne Therapeutics Announces Expanded Debt Facility of Up To $400 Million with Hercules Capital, Inc.– Up to $125 million in additional borrowing capacity provides further strategic flexibility – Read more »
- Glass House Brands Announces its Deconsolidation of its Dual-Use Business and its Application for Uplisting of Shares to NYSELONG BEACH, Calif. and TORONTO, June 17, 2026 (GLOBE NEWSWIRE) — Glass House Brands Inc. (“Glass House” or the “Company”)… Read more »
- uniQure Announces Plan for BLA Submission for AMT-130 in Huntington’s Disease~ 3-year analysis from the Phase I/II study can serve as the primary basis of a Biologics License Application for… Read more »
- Sernova Biotherapeutics Receives FDA Orphan Drug Designation for Autologous Islet Transplantation for Prevention of Diabetes Due to Total PancreatectomyTORONTO and BOSTON, June 17, 2026 (GLOBE NEWSWIRE) — Sernova Biotherapeutics Inc. (“Sernova” or the “Company”) (TSX: SVA) (OTC: SEOVF)… Read more »
- Can-Fite to Present Late-Stage Clinical Pipeline and Licensing Opportunities at BIO International Convention 2026Company to Conduct Partnering Meetings Focused on Oncology, Liver Disease and Inflammatory Disease Read more »
BrewDog Turns Up Father’s Day Across the U.K. with Gift-Ready Beer, Custom Cans and Dads Eat Free
From standout beer gifts to nationwide bar experiences, BrewDog is bringing bold flavour and big Father’s Day energy to dads… Read more »- Rezolute Highlights Results Presented from Natural History Outcomes Studies and its Ersodetug Clinical Program in Hyperinsulinism at Annual Meeting of the Endocrine SocietyPresentations included analyses of natural history and adverse outcomes in congenital hyperinsulinism (HI), as well as previously reported results from… Read more »
- NexTel Medical Outlines its Revenue Model Using the Innovation of Tomorrow: Synergy of Advanced Medical Technologies and Massive Sales Infrastructure Primed to Drive Exponential GrowthOTCID:MAJI announced a strategic pivot, evolutionary restructuring, and operational alignment designed to transition the company Read more »
- HMNC Brain Health appoints Dr. Bjørn Grønning as Chief Medical OfficerMUNICH, Germany, June 17, 2026 – HMNC Brain Health (“HMNC” or the “Company”), a clinical-stage neuroscience company, today announced the… Read more »
- Step Pharma advances dencatistat into phase 2 clinical trial for essential thrombocythaemiaSaint-Genis-Pouilly, France, 17 June 2026 – Step Pharma (“the Company”), the global leader in CTPS1 inhibition for targeted cancer treatment, today… Read more »
- SYNAPSE-CMT Phase 2a Clinical Study Data Presented in Late-Breaking Oral Presentation at 2026 PNS Annual MeetingAarhus, Denmark, 17 June 2026 – NMD Pharma A/S, a clinical-stage biotechnology company dedicated to developing novel therapies to restore… Read more »
- Adaptive Biotechnologies Corporation Prices Upsized $300 Million Convertible Senior Notes OfferingSEATTLE, June 17, 2026 (GLOBE NEWSWIRE) — Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT) today announced the pricing of its… Read more »
- Christian Wichert appointed Chief Executive Officer to lead next phase of growthChristian Wichert appointed Chief Executive Officer to lead next phase of growth Read more »